IL32673A - A granular material containing oily or liquid therapeutically usable furanosides and a process for its manufacture - Google Patents
A granular material containing oily or liquid therapeutically usable furanosides and a process for its manufactureInfo
- Publication number
- IL32673A IL32673A IL32673A IL3267369A IL32673A IL 32673 A IL32673 A IL 32673A IL 32673 A IL32673 A IL 32673A IL 3267369 A IL3267369 A IL 3267369A IL 32673 A IL32673 A IL 32673A
- Authority
- IL
- Israel
- Prior art keywords
- weight
- parts
- furanoside
- process according
- concentration
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 23
- 239000008187 granular material Substances 0.000 title claims description 14
- 239000007788 liquid Substances 0.000 title claims description 12
- 238000004519 manufacturing process Methods 0.000 title claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 claims description 12
- 239000000391 magnesium silicate Substances 0.000 claims description 12
- 229940099273 magnesium trisilicate Drugs 0.000 claims description 12
- 229910000386 magnesium trisilicate Inorganic materials 0.000 claims description 12
- 235000019793 magnesium trisilicate Nutrition 0.000 claims description 12
- 239000003463 adsorbent Substances 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 229920003023 plastic Polymers 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 229920002554 vinyl polymer Polymers 0.000 claims description 4
- 125000001931 aliphatic group Chemical group 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 2
- 239000004215 Carbon black (E152) Substances 0.000 claims 3
- 229930195733 hydrocarbon Natural products 0.000 claims 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- ULLNJSBQMBKOJH-VIVFLBMVSA-N (3R,4R,5R)-5-[(1R)-1,2-bis(phenylmethoxy)ethyl]-2-ethoxy-4-phenylmethoxy-3-oxolanol Chemical group C([C@H]([C@H]1OC([C@@H]([C@H]1OCC=1C=CC=CC=1)O)OCC)OCC=1C=CC=CC=1)OCC1=CC=CC=C1 ULLNJSBQMBKOJH-VIVFLBMVSA-N 0.000 claims 1
- 102100032341 PCNA-interacting partner Human genes 0.000 claims 1
- 101710196737 PCNA-interacting partner Proteins 0.000 claims 1
- 229920001800 Shellac Polymers 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 150000002430 hydrocarbons Chemical class 0.000 claims 1
- 125000005641 methacryl group Chemical group 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims 1
- 239000004208 shellac Substances 0.000 claims 1
- 229940113147 shellac Drugs 0.000 claims 1
- 235000013874 shellac Nutrition 0.000 claims 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 claims 1
- 235000012239 silicon dioxide Nutrition 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 239000008119 colloidal silica Substances 0.000 description 6
- 239000008298 dragée Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 5
- 229910052749 magnesium Inorganic materials 0.000 description 5
- 239000011777 magnesium Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- ULLNJSBQMBKOJH-JPHCZMGXSA-N (2s,3r,4r,5r)-5-[(1r)-1,2-bis(phenylmethoxy)ethyl]-2-ethoxy-4-phenylmethoxyoxolan-3-ol Chemical compound C([C@H]([C@H]1O[C@@H]([C@@H]([C@H]1OCC=1C=CC=CC=1)O)OCC)OCC=1C=CC=CC=1)OCC1=CC=CC=C1 ULLNJSBQMBKOJH-JPHCZMGXSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 229960003567 tribenoside Drugs 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- GUBGYTABKSRVRQ-QRZGKKJRSA-N beta-cellobiose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QRZGKKJRSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000024033 toxin binding Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH1170468 | 1968-08-05 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL32673A0 IL32673A0 (en) | 1969-09-25 |
| IL32673A true IL32673A (en) | 1973-11-28 |
Family
ID=4376070
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL32673A IL32673A (en) | 1968-08-05 | 1969-07-22 | A granular material containing oily or liquid therapeutically usable furanosides and a process for its manufacture |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US3594474A (enExample) |
| AT (1) | AT290731B (enExample) |
| BE (1) | BE737053A (enExample) |
| BG (1) | BG17466A3 (enExample) |
| BR (1) | BR6911321D0 (enExample) |
| CA (1) | CA938889A (enExample) |
| CY (1) | CY790A (enExample) |
| DE (1) | DE1938108C3 (enExample) |
| DK (1) | DK123912B (enExample) |
| FI (1) | FI50058C (enExample) |
| FR (1) | FR2015053A1 (enExample) |
| GB (1) | GB1259387A (enExample) |
| IE (1) | IE33246B1 (enExample) |
| IL (1) | IL32673A (enExample) |
| IT (1) | IT1035508B (enExample) |
| MY (1) | MY7500079A (enExample) |
| NL (1) | NL162837C (enExample) |
| NO (1) | NO129183B (enExample) |
| OA (1) | OA03604A (enExample) |
| PL (1) | PL88871B1 (enExample) |
| RO (1) | RO57881A (enExample) |
| SE (1) | SE363735B (enExample) |
| SU (1) | SU409407A3 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4195078A (en) * | 1979-03-09 | 1980-03-25 | Eli Lilly And Company | Nabilone granulation |
| DE3773926D1 (de) * | 1987-07-22 | 1991-11-21 | Farvalsa Ag | Feuchtigkeitsstabile feste valproinsaeure-zubereitung und verfahren zu ihrer herstellung. |
-
1969
- 1969-07-22 IL IL32673A patent/IL32673A/en unknown
- 1969-07-23 CA CA057745A patent/CA938889A/en not_active Expired
- 1969-07-25 US US845038A patent/US3594474A/en not_active Expired - Lifetime
- 1969-07-26 DE DE1938108A patent/DE1938108C3/de not_active Expired
- 1969-07-29 FR FR6925823A patent/FR2015053A1/fr not_active Withdrawn
- 1969-07-29 IE IE1051/69A patent/IE33246B1/xx unknown
- 1969-07-30 BG BG012772A patent/BG17466A3/xx unknown
- 1969-07-30 FI FI692257A patent/FI50058C/fi active
- 1969-07-31 GB GB1259387D patent/GB1259387A/en not_active Expired
- 1969-07-31 CY CY790A patent/CY790A/xx unknown
- 1969-08-04 SU SU1356872A patent/SU409407A3/ru active
- 1969-08-04 NO NO03188/69A patent/NO129183B/no unknown
- 1969-08-04 AT AT748569A patent/AT290731B/de not_active IP Right Cessation
- 1969-08-04 BE BE737053D patent/BE737053A/xx not_active IP Right Cessation
- 1969-08-04 IT IT39194/69A patent/IT1035508B/it active
- 1969-08-04 SE SE10870/69A patent/SE363735B/xx unknown
- 1969-08-04 NL NL6911864.A patent/NL162837C/xx not_active IP Right Cessation
- 1969-08-04 DK DK418069AA patent/DK123912B/da not_active IP Right Cessation
- 1969-08-04 PL PL1969135222A patent/PL88871B1/pl unknown
- 1969-08-05 OA OA53697A patent/OA03604A/xx unknown
- 1969-08-05 BR BR211321/69A patent/BR6911321D0/pt unknown
- 1969-08-05 RO RO@@A patent/RO57881A/ro unknown
-
1970
- 1970-09-18 US US73606A patent/US3655870A/en not_active Expired - Lifetime
-
1975
- 1975-12-30 MY MY79/75A patent/MY7500079A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FR2015053A1 (enExample) | 1970-04-24 |
| NO129183B (enExample) | 1974-03-11 |
| AT290731B (de) | 1971-06-11 |
| NL6911864A (enExample) | 1970-02-09 |
| SU409407A3 (enExample) | 1973-11-30 |
| BE737053A (enExample) | 1970-02-04 |
| IL32673A0 (en) | 1969-09-25 |
| MY7500079A (en) | 1975-12-31 |
| DE1938108A1 (de) | 1970-02-26 |
| IE33246L (en) | 1970-02-05 |
| DK123912B (da) | 1972-08-21 |
| GB1259387A (enExample) | 1972-01-05 |
| NL162837C (nl) | 1980-07-15 |
| US3594474A (en) | 1971-07-20 |
| SE363735B (enExample) | 1974-02-04 |
| OA03604A (fr) | 1971-03-30 |
| IT1035508B (it) | 1979-10-20 |
| IE33246B1 (en) | 1974-05-01 |
| NL162837B (nl) | 1980-02-15 |
| CA938889A (en) | 1973-12-25 |
| CY790A (en) | 1976-06-01 |
| FI50058C (fi) | 1975-12-10 |
| DE1938108C3 (de) | 1974-01-03 |
| BR6911321D0 (pt) | 1973-02-13 |
| RO57881A (enExample) | 1974-11-15 |
| US3655870A (en) | 1972-04-11 |
| BG17466A3 (bg) | 1973-11-10 |
| PL88871B1 (enExample) | 1976-10-30 |
| FI50058B (enExample) | 1975-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2390933C (en) | Oral solid preparation comprising 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide | |
| CA1149742A (en) | Sustained release indomethacin | |
| US3773920A (en) | Sustained release medicinal composition | |
| KR910002670B1 (ko) | 아모술랄롤 하이드로클로라이드 지속성 제제의 제조방법 | |
| CZ369292A3 (en) | Per-orally applicable form of a medicament for treating central states of dopamine insufficiency | |
| EP1334725B1 (fr) | Utilisation d'une composition estroprogestative en tant que contraceptif oral | |
| EP0500851B1 (en) | Process for the preparation of a tablet or dragee composition containing a heat-, light- and moisture-sensitive active ingredient having monoclinic crystal structure | |
| JP2916227B2 (ja) | ビタミンｂ▲下１▼▲下２▼類含有組成物 | |
| EP0921793B1 (en) | Solid, non-deliquescent formulations of sodium valproate | |
| KR100635018B1 (ko) | (7α, 17α)-17-히드록시-7-메틸-19-노르-17-프레근-5(10)-엔-20-인-3-온의 고순도 화합물을 제조하는 방법 | |
| IL32673A (en) | A granular material containing oily or liquid therapeutically usable furanosides and a process for its manufacture | |
| GB1582162A (en) | Stable prostaglandin composition and process for the preparation thereof | |
| JP3995414B2 (ja) | 安定な医薬組成物 | |
| CA1248524A (en) | Complexes of prostaglandins | |
| US3068147A (en) | Analgesic compositions containing o-propoxybenzamide with salicylamide or acetyl-p-aminophenol or mixtures thereof | |
| GB2058565A (en) | Layer tablets | |
| JPH11335302A (ja) | 安定な医薬組成物 | |
| US4010275A (en) | Treatment of osteoarthritis | |
| WO2001007024A2 (en) | Paracetamol and drotaverine containing composition | |
| GB2061111A (en) | Long acting pharmaceutical composition | |
| JPH01203329A (ja) | 粒状ないし粉末状のビタミンｂ↓１↓２類含有組成物 | |
| EP0431759B1 (en) | Process for the preparation of a ranitidine resin absorbate | |
| KR100247845B1 (ko) | 신경 보호제 | |
| US20050013924A1 (en) | Method for formulating healthcare products with enhanced stability | |
| JPH04217915A (ja) | ４−エチル−２−ヒドロキシイミノ−５−ニトロ−３−ヘキセンアミド含有製剤用の安定化剤、安定化方法及び安定化された製剤 |